Ann: Suspension from Official Quotation - Annual Listing Fee, page-44

off interest, imho, is that since then, as per ann August 7th, SB group should now be a consolidated top twenty entity at 130 plus, (?) followed by a far second of HSBC at 97 plus, (if consolidated).

Certainly makes SB very influential towards the future of Admedus.

As regards too ‘oversight’ of Admedus, very poor poor form, imo, by any measure at this particularly sensitive time when ‘confidence’ is everything.

Folk should really reflect on the importance of the companies strategy to move forward, RIs at this time, 55% or so, are the majority holders, long term at that, you would imagine ‘their’ interests would be considered.
Future CR, IF, will change that landscape drastically, imo.

That consideration, imo, should include a announcement clarifying the ‘oversight’, thus negating, imo, the scenarios as listed per 2.1 ASX listing rules.


On reflection, those scenarios do offer some possible relief to current RIs, assets sold at fair deeming rate rather than this company CRed to the ‘death’ and assets sold at ‘mates’ rates.

Especially the issue of protecting assets, (by delisting?) at a fair deeming value versus those assets being sold at ‘fire sale’ prices, that is, below fair value; AI 6 to 9 mill plus, + worth of Adapt IP + ‘worth’ of TAVR IP, any guesses!

Worth of TAVR, big call, immediate future will be very telling, imo, deal/no deal?, what does it really have compared to the well established comp?, a ‘missing’ link, as in compelling improvement to existing tech, would make it very valuable to all existing players then.

Best interests of RIs will need what?, ‘rainmaker of future deal/s for IP’, or future CR to keep the company ‘live’, to further advance cause of SB/SIO, or delisting.

Imo, the first and third options may be the most favourable, happy, as usual, to hear counter dialogue.